Recent weeks have seen heightened debate over the need for phase 3 confirmatory trials for biosimilars, with some stakeholders calling these trials unnecessary and others going so far as to call them unethical. During the SMi 9th annual conference on Biosimilars and Biobetters, held September 26-27 in London, United Kingdom, Uwe Gudat, MD, who serves as head of clinical safety and pharmacovigilance at Fresenius Kabi, weighed in. “The subject I raise is rather provocative,” he acknowledged.
Recent weeks have seen heightened debate over the need for phase 3 confirmatory trials for biosimilars, with some stakeholders calling these trials unnecessary and others going so far as to call them unethical.
During the SMi 9th annual conference on Biosimilars and Biobetters, held September 26-27 in London, United Kingdom, Uwe Gudat, MD, who serves as head of clinical safety and pharmacovigilance at Fresenius Kabi, weighed in. “The subject I raise is rather provocative,” he acknowledged, adding that he was expressing personal views that may not align with those of his organization.
The classical approach to product development, said Gudat, is “a pretty complex affair, and you’ve got a lot of questions to answer,” but the same is not necessarily true of biosimilars, where the goal of clinical trials is to address residual uncertainty. “We use the same tools” as innovator developers, he said, “with different objectives.”
Read more about the controversy over phase 3 clinical trials for biosimilars.
Given advances in analytical methods for understanding the structure—function relationship of biologic medicines, developers now have less residual uncertainty concerning their molecules. “Once I know what I’ve got, I pretty well know what it does,” he said. Given this fact, “Why bother with clinical studies? Why are we doing this?”
Said Gudat, “There’s a backroad that we sometimes forget. The clinic informs what type of analytical characterization is underlying, which informs of the structure [of the molecule]. The human body is a catch-all assay,” he added, that can potentially find a rupture in the analytical characterization of the biosimilar.
However, despite the fact that the clinical trial is being used as a safety net for potential errors, approaches to conducting these trials are remarkably variable. Biosimilars of rituximab, for example, are being tested in a wide variety of indications with small sample sizes in each indication. “There seems to be no single answer to the clinical study question” in terms of study population, despite the need to test these products in the most sensitive population. “There’s confusion in the space,” said Gudat. Furthermore, given that large sample sizes would likely be necessary to truly reduce residual uncertainty about a molecule, and given that clinical trials carry an inherent risk for patients, further consideration about the need for these trials may be warranted.
Gudat also noted that the current EU clinical trials directive holds that repetitive tests should not be carried out; this fact raises the question of whether repeatedly characterizing the safety profile of a drug in healthy volunteers in order to facilitate biosimilar studies is merely generating evidence that is already known, as well as the question of whether the practice contradicts the directive.
However, Gudat did not go so far as to say that clinical trials for these products should become a thing of the past. Instead, in his view, they may warrant rethinking. In undertaking clinical trials, he said, developers may be underutilizing biodynamic markers as a way to address residual uncertainty.
Pharmacodynamic (PD) markers, he explained, have been developed and used as stand-ins for clinical endpoints, and according to the FDA, use of an established PD marker can be used to add to the overall demonstration of biosimilarity. Using a broader panel of biomarkers, said Gudat, could have value.
In closing his talk, Gudat noted that “do we still need clinical trials for biosimilars?” may be the wrong question altogether. Instead, he proposed, “do we need to approach clinical development of a biosimilar with a completely different mindset?” may be the more important question.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.